Previous 10 | Next 10 |
2023-08-11 16:17:21 ET Exicure press release ( NASDAQ: XCUR ): Q2 GAAP EPS of -$0.68. Cash, cash equivalents and restricted cash were $3.5 million as of June 30, 2023, as compared to $9.8 million as of December 31, 2022. The Company expects that its cash and cash equiv...
Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activiti...
2023-07-17 01:57:28 ET Exicure press release ( NASDAQ: XCUR ): Q1 GAAP EPS of -$0.70. Cash, cash equivalents and restricted cash were $11.2 million as of March 31, 2023, as compared to $9.8 million as of December 31, 2022. The company expects that its cash and cash equ...
Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activiti...
2023-07-14 10:01:23 ET Gainers: PainReform ( PRFX ) +112% . Acadia Pharmaceuticals ( ACAD ) +15% . Nutriband ( NTRB ) +14% . Arcturus Therapeutics ( ARCT ) +10% . Exicure ( XCUR ) +7% . Losers: Theseus Pharmaceuticals ( ...
2023-07-14 08:34:41 ET EdtechX Holdings ( NASDAQ: EDTX ) +68% . ARB IOT Group ( ARBB ) +48% . PainReform ( PRFX ) +35% . Nutriband ( NTRB ) +35% . Western Acquisition Ventures ( WAVS ) +20% . Nik...
2023-07-13 10:09:11 ET Gainers: Applied DNA Sciences ( APDN ) +29% . 60 Degrees Pharmaceuticals ( SXTP ) +21% . Exicure ( XCUR ) +13% . Psychemedics ( PMD ) +11% . Plus Therapeutics ( PSTV ) +9% . Losers: First W...
2023-05-26 16:18:18 ET Exicure ( NASDAQ: XCUR ) said Friday that the company's board supports CEO Jung Sang Kim's view to continue exploring strategic alternatives for the company. "These efforts include the possible sale of certain of the company’s...
Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, previously announced an ongoing strategy to explore strategic...
2023-05-19 16:23:49 ET Exicure ( NASDAQ: XCUR ) said Friday it received a notice of non-compliance from Nasdaq for not filing its form 10-Q for the quarterly period ended March 31, 2023 on time. The company said is working diligently to complete its form 10-Q and intends to fi...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
Exicure, Inc. (Nasdaq: XCUR, the “Company”), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspe...
Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activitie...